Last reviewed · How we verify
Florastamin[18F] Injection
Florastamin[18F] is a fluorine-18 labeled radiopharmaceutical that targets bacterial infection and inflammation for positron emission tomography (PET) imaging.
Florastamin[18F] is a fluorine-18 labeled radiopharmaceutical that targets bacterial infection and inflammation for positron emission tomography (PET) imaging. Used for Detection and localization of bacterial infections, Imaging of inflammatory lesions.
At a glance
| Generic name | Florastamin[18F] Injection |
|---|---|
| Sponsor | HTA Co., Ltd. |
| Drug class | PET imaging agent / radiopharmaceutical |
| Modality | Small molecule |
| Therapeutic area | Diagnostic Imaging / Infectious Disease |
| Phase | Phase 3 |
Mechanism of action
This agent is designed as a PET imaging tracer that accumulates in areas of bacterial infection and inflammatory lesions, allowing for non-invasive visualization and localization of infection sites. The [18F] fluorine-18 isotope enables real-time imaging through PET scanning, facilitating early detection and monitoring of infectious and inflammatory conditions.
Approved indications
- Detection and localization of bacterial infections
- Imaging of inflammatory lesions
Common side effects
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Florastamin[18F] Injection CI brief — competitive landscape report
- Florastamin[18F] Injection updates RSS · CI watch RSS
- HTA Co., Ltd. portfolio CI